Masahiro Onozawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masahiro Onozawa has a total of 489 co-authors. Here are the top co-authors by number of shared publications:
Takanori Teshima
18 shared publications- Takanori Teshima
Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
18 shared publications Satoshi Hashino
Hokkaido University
17 shared publicationsTakeshi Kondo
Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
16 shared publicationsJunichi Hashiguchi
Department of Internal Medicine, Kitami Red Cross Hospital, Kitami, Japan
13 shared publications- Takeshi Kondo
Blood Disorders Center, Aiiku Hospital, Sapporo, Japan
12 shared publications
Latest Publications
- 1 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6754-6763
Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML
BMT CTN 1506 (MORPHO) was a phase 3 study of post–hematopoietic cell transplantation (HCT) maintenance with gilteritinib vs placebo for patients with FLT3-ITD–mutated acute myeloid leukemia (AML) in first remission. Subgroup analysis indicated a significant benefit of post-HCT gilteritinib for participants in North America but no benefit for those in Europe or Asia. We conducted a post hoc analysis of the data focusing on the time from AML diagnosis to HCT, pre-HCT FLT3 inhibitor use, and FLT3-ITD measurable residual disease (MRD). Participants who underwent transplantation <120 days from AML diagnosis and/or those treated with FLT3 inhibition before HCT were more likely to have improved survival from post-HCT gilteritinib. Pre-HCT MRD levels were higher (P = .001) in participants who underwent transplantation within 120 days from diagnosis and in those treated with an FLT3 inhibitor before HCT and underwent transplantation within 120 days (P = .008). Pre-HCT MRD was dependent on both FLT3 inhibitor use and time to HCT, because participants treated with successive courses of chemotherapy + FLT3 inhibition had successively lower MRD by the time of HCT. Time from AML diagnosis to HCT and pre-HCT FLT3 inhibitor use both appeared to affect MRD levels immediately before HCT, and geographic differences in these 2 practice patterns likely accounted for the observed regional differences in benefit from post-HCT gilteritinib. Increasing the number of courses of treatment before HCT may lower MRD sufficiently to eliminate the need for post-HCT inhibition, but with a presumed risk of some patients experiencing early progression. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
- 1 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6754-6763
Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML
BMT CTN 1506 (MORPHO) was a phase 3 study of post–hematopoietic cell transplantation (HCT) maintenance with gilteritinib vs placebo for patients with FLT3-ITD–mutated acute myeloid leukemia (AML) in first remission. Subgroup analysis indicated a significant benefit of post-HCT gilteritinib for participants in North America but no benefit for those in Europe or Asia. We conducted a post hoc analysis of the data focusing on the time from AML diagnosis to HCT, pre-HCT FLT3 inhibitor use, and FLT3-ITD measurable residual disease (MRD). Participants who underwent transplantation <120 days from AML diagnosis and/or those treated with FLT3 inhibition before HCT were more likely to have improved survival from post-HCT gilteritinib. Pre-HCT MRD levels were higher (P = .001) in participants who underwent transplantation within 120 days from diagnosis and in those treated with an FLT3 inhibitor before HCT and underwent transplantation within 120 days (P = .008). Pre-HCT MRD was dependent on both FLT3 inhibitor use and time to HCT, because participants treated with successive courses of chemotherapy + FLT3 inhibition had successively lower MRD by the time of HCT. Time from AML diagnosis to HCT and pre-HCT FLT3 inhibitor use both appeared to affect MRD levels immediately before HCT, and geographic differences in these 2 practice patterns likely accounted for the observed regional differences in benefit from post-HCT gilteritinib. Increasing the number of courses of treatment before HCT may lower MRD sufficiently to eliminate the need for post-HCT inhibition, but with a presumed risk of some patients experiencing early progression. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
- 7 September 2026
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 65 (9) , e70171
Tandem Double Inversion Resolves the Structural Paradox Underlying Recurrent KAT6A::NCOA2 Fusion in Acute Myeloid Leukemia
The KAT6A::NCOA2 (formerly MOZ::TIF2 ) fusion is an extremely rare recurrent genetic abnormality in acute myeloid leukemia (AML), with only nine cases reported to date. It has consistently been associated with inv(8)(p11q13). However, the genomic mechanism underlying this fusion has remained unresolved. Because both KAT6A and NCOA2 are transcribed in the same reverse orientation on chromosome 8, a simple inversion is structurally insufficient to generate a transcriptionally competent fusion transcript, creating a long‐standing cytogenetic paradox. We analyzed an AML case harboring a KAT6A::NCOA2 fusion using targeted genomic profiling and breakpoint‐level validation. In addition to the canonical KAT6A::NCOA2 fusion, sequencing identified an unexpected MTFR1::KAT6A rearrangement. Since MTFR1 is located between KAT6A and NCOA2 on chromosome 8, we hypothesized a complex intrachromosomal rearrangement. Genomic breakpoint analysis revealed that the fusion was generated not by a single inv(8), but by two adjacent intrachromosomal inversions forming a tandem double inversion. This rearrangement reoriented genomic segments to place KAT6A and NCOA2 in a transcriptionally compatible configuration, enabling fusion formation. These findings resolve the structural paradox of KAT6A::NCOA2 ‐positive AML by demonstrating that a cytogenetically apparent inv(8)(p11q13) can conceal a tandem double‐inversion architecture that reorients KAT6A and NCOA2 into a transcriptionally compatible configuration.
- 7 September 2026
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 65 (9) , e70171
Tandem Double Inversion Resolves the Structural Paradox Underlying Recurrent KAT6A::NCOA2 Fusion in Acute Myeloid Leukemia
The KAT6A::NCOA2 (formerly MOZ::TIF2 ) fusion is an extremely rare recurrent genetic abnormality in acute myeloid leukemia (AML), with only nine cases reported to date. It has consistently been associated with inv(8)(p11q13). However, the genomic mechanism underlying this fusion has remained unresolved. Because both KAT6A and NCOA2 are transcribed in the same reverse orientation on chromosome 8, a simple inversion is structurally insufficient to generate a transcriptionally competent fusion transcript, creating a long‐standing cytogenetic paradox. We analyzed an AML case harboring a KAT6A::NCOA2 fusion using targeted genomic profiling and breakpoint‐level validation. In addition to the canonical KAT6A::NCOA2 fusion, sequencing identified an unexpected MTFR1::KAT6A rearrangement. Since MTFR1 is located between KAT6A and NCOA2 on chromosome 8, we hypothesized a complex intrachromosomal rearrangement. Genomic breakpoint analysis revealed that the fusion was generated not by a single inv(8), but by two adjacent intrachromosomal inversions forming a tandem double inversion. This rearrangement reoriented genomic segments to place KAT6A and NCOA2 in a transcriptionally compatible configuration, enabling fusion formation. These findings resolve the structural paradox of KAT6A::NCOA2 ‐positive AML by demonstrating that a cytogenetically apparent inv(8)(p11q13) can conceal a tandem double‐inversion architecture that reorients KAT6A and NCOA2 into a transcriptionally compatible configuration.
- 17 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 994.e1-994.e11
Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial
- 17 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 994.e1-994.e11
Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial
- 22 April 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (3) , 1-7
Philadelphia chromosome–negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study
Chronic myelogenous leukemia that carries the BCR::ABL1 fusion gene without cytogenetically detectable Philadelphia (Ph) chromosomes is termed masked Ph. However, the prevalence and clinical relevance of masked Ph in acute lymphoblastic leukemia (ALL) remain unclear. Using the Hokkaido Leukemia Net real-world multicenter cohort, we analyzed 160 B-cell ALL patients diagnosed between 2017 and 2024 with available cytogenetic and molecular data. Among 92 BCR::ABL1-positive cases, 19 (20.7%) lacked a cytogenetically visible Ph chromosome and were classified as masked-Ph ALL. Compared with Ph + ALL, masked-Ph patients were older and had lower white blood cell counts and bone marrow blast percentages at diagnosis. Most BCR::ABL1-positive patients received tyrosine kinase inhibitors (TKIs) during induction, resulting in comparable complete remission rates and similar overall survival between masked-Ph and Ph + ALL; both groups showed superior outcomes compared with BCR::ABL1-negative ALL. The number of metaphases analyzed by G-banding was significantly lower in masked-Ph ALL, suggesting underdetection by conventional cytogenetics. One case exhibited an atypical FISH pattern consistent with a cryptic microinsertion. These findings indicate that masked-Ph ALL is relatively common and may be overlooked without molecular testing, underscoring the importance of incorporating RT-PCR and FISH at diagnosis.
- 22 April 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (3) , 1-7
Philadelphia chromosome–negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study
Chronic myelogenous leukemia that carries the BCR::ABL1 fusion gene without cytogenetically detectable Philadelphia (Ph) chromosomes is termed masked Ph. However, the prevalence and clinical relevance of masked Ph in acute lymphoblastic leukemia (ALL) remain unclear. Using the Hokkaido Leukemia Net real-world multicenter cohort, we analyzed 160 B-cell ALL patients diagnosed between 2017 and 2024 with available cytogenetic and molecular data. Among 92 BCR::ABL1-positive cases, 19 (20.7%) lacked a cytogenetically visible Ph chromosome and were classified as masked-Ph ALL. Compared with Ph + ALL, masked-Ph patients were older and had lower white blood cell counts and bone marrow blast percentages at diagnosis. Most BCR::ABL1-positive patients received tyrosine kinase inhibitors (TKIs) during induction, resulting in comparable complete remission rates and similar overall survival between masked-Ph and Ph + ALL; both groups showed superior outcomes compared with BCR::ABL1-negative ALL. The number of metaphases analyzed by G-banding was significantly lower in masked-Ph ALL, suggesting underdetection by conventional cytogenetics. One case exhibited an atypical FISH pattern consistent with a cryptic microinsertion. These findings indicate that masked-Ph ALL is relatively common and may be overlooked without molecular testing, underscoring the importance of incorporating RT-PCR and FISH at diagnosis.
- Open Access
- 19 March 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (2) , 167-176
Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan
Venetoclax (VEN), a BCL-2 inhibitor, was approved in Japan in March 2021, for acute myeloid leukemia (AML). We retrospectively analyzed the impact of VEN approval on treatment patterns and outcomes in older AML patients aged 65–74 years unfit for intensive chemotherapy in Japan. Using the Hokkaido Leukemia Net database, we categorized 101 patients into pre-VEN ( n = 46) and post-VEN ( n = 55) cohorts, excluding those who had acute promyelocytic leukemia or received intensive chemotherapy. Following VEN approval, VEN + azacitidine (AZA) became the most frequently used initial regimen (56%). Despite higher rates of TP53 mutations and complex karyotypes (35.5%), VEN + AZA achieved comparable response rates (CR + CRi: 64.5%) and overall survival (OS, median 11.7 months) to r7 + 3 (CR + CRi: 64.5%, median OS: 13.1 months), and superior outcomes to cytarabine + aclarubicin + G-CSF (CAG, CR + CRi 37.5%, median OS 6.8 months) or AZA monotherapy (CR + CRi 12.5%, median OS 4.5 months). Early mortality at 60 days from diagnosis was lower with VEN + AZA (3.2%) than with reduced-dose cytarabine plus anthracycline (r7 + 3) (12.9%), CAG (26.7%), or AZA monotherapy (18.8%). Our findings demonstrate a substantial shift in real-world treatment practices following VEN approval and suggest that VEN + AZA is an effective option for older AML patients with adverse genetic features.
- 19 March 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (2) , 167-176
Open AccessReal-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan
Venetoclax (VEN), a BCL-2 inhibitor, was approved in Japan in March 2021, for acute myeloid leukemia (AML). We retrospectively analyzed the impact of VEN approval on treatment patterns and outcomes in older AML patients aged 65–74 years unfit for intensive chemotherapy in Japan. Using the Hokkaido Leukemia Net database, we categorized 101 patients into pre-VEN ( n = 46) and post-VEN ( n = 55) cohorts, excluding those who had acute promyelocytic leukemia or received intensive chemotherapy. Following VEN approval, VEN + azacitidine (AZA) became the most frequently used initial regimen (56%). Despite higher rates of TP53 mutations and complex karyotypes (35.5%), VEN + AZA achieved comparable response rates (CR + CRi: 64.5%) and overall survival (OS, median 11.7 months) to r7 + 3 (CR + CRi: 64.5%, median OS: 13.1 months), and superior outcomes to cytarabine + aclarubicin + G-CSF (CAG, CR + CRi 37.5%, median OS 6.8 months) or AZA monotherapy (CR + CRi 12.5%, median OS 4.5 months). Early mortality at 60 days from diagnosis was lower with VEN + AZA (3.2%) than with reduced-dose cytarabine plus anthracycline (r7 + 3) (12.9%), CAG (26.7%), or AZA monotherapy (18.8%). Our findings demonstrate a substantial shift in real-world treatment practices following VEN approval and suggest that VEN + AZA is an effective option for older AML patients with adverse genetic features.
- Open Access
- 6 February 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Clustering of students in pre-clinical medical education and identification of academic performance profiles: does online education work for all medical students?
Unlike variable-centered analysis, person-centered analysis facilitates the development of more personalized learning. In this study, we investigated the p
- 6 February 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Open AccessClustering of students in pre-clinical medical education and identification of academic performance profiles: does online education work for all medical students?
Unlike variable-centered analysis, person-centered analysis facilitates the development of more personalized learning. In this study, we investigated the p
- Open Access
- 20 January 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Primary Cutaneous Adult T-cell Leukaemia/Lymphoma Presenting as Generalized Purpura
- 20 January 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessPrimary Cutaneous Adult T-cell Leukaemia/Lymphoma Presenting as Generalized Purpura
- 6 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (3) , 339.e1-339.e9
Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study
- 6 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (3) , 339.e1-339.e9
Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study
- Open Access
- 27 September 2025
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 58
Asphyxiation due to obstructive fibrinous tracheal pseudomembrane after closure of repeated tracheostomy in a case of von Recklinghausen disease
- 27 September 2025
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 58
Open AccessAsphyxiation due to obstructive fibrinous tracheal pseudomembrane after closure of repeated tracheostomy in a case of von Recklinghausen disease